Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of KD2-396 versus DTaP-sIPV/Hib plus hepatitis B vaccine in infants
jRCT2031250804Phase 3Active, not recruiting
- Sponsor
- KM Biologics
- Start
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of KD2-396 in pertussis, diphtheria, Tetanus and 3 more (2 arms), sponsored by KM Biologics. Primary endpoints: Protective antibody response against hepatitis B surface antigen and Protective antibody response against pertussis, diphtheria, tetanus, poliovirus, and PRP. Started Mar 2026; status: active, not recruiting.
02
Drugs
KD2-396
03
Conditions
pertussisdiphtheriaTetanuspoliomyelitisHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on jRCT2031250804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250804.